A
Aplagon
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutic solutions for severe cardiovascular diseases
About Aplagon
Developer of antithrombotic compounds designed to treat complications of vascular intervention-related blood vessel occlusions. The company's compounds are engaged in developing biological mimetics of heparin proteoglycan, for the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries, enabling patients to get effective antithrombotic medicines with important safety advantages.
Source: Dealroom company dataAt a glance
- Founded
- 2009
- Headquarters
- Helsinki, Finland
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Innovestor
European Innovation Council
Series A4 investors entered at this stage
EIC Fund
Fåhraeus Startup and Growth- JFJenny and Antti Wihuri Foundation
Gösta Serlachius Fine Arts Foundation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aplagon on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aplagon on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.